Member Info for Newuncle

Go Go ENET!!!

WOOOOOOOOOOOSH

KA-BOOM!!!!!! NT to buy any

Nasdaq listing on the cards here

Hi Tricky,

You alright

£100 per share soon

Multi billion company for peanuts.

£100 billion global market here

Amazing.......

Tricky,

yup, wonder how much longer will they allow this to go on?

Tricky another 100k taken by our buyer(s) today?

At 34p.....good news?

We at the National Alliance of Stare Prostate Cancer Coalitions (NASPCC) endorse the early detection of potentially lethal prostate cancer which requires better diagnostics and more intentional screening for appropriate populations. www.NASPCC.org

It is an innovation that chief executive, Jon Burrows, wants to get into the hands of GPs in the NHS as quickly as he can.

He has yet to apply to National Institute for Health and Care Excellence (Nice), the health body which approves new tests and drugs, but hopes the NHS will fast-track the test once it's been cleared.

Both Nice and the NHS should move swiftly. Around 50,000 men are diagnosed with prostate cancer each year, so the earlier the diagnosis, the better the prognosis. As Burrows told me, using the new test will save the NHS a huge amount of money because clinics won't need to carry out biopsies or use MRIs scans.

OBD has participated in 40+ partnerships with pharma and leading institutions, including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital, and Mitsubishi Tanabe Pharma

Wonder who?

The company’s flagship product, EpiSwitch CiRT (Checkpoint inhibitor Response Test), is a first-of-its-kind smart blood test for cancer patients that provides guidance on navigating the toughest challenges of immunotherapy like treatment planning, pseudo-progression, and adverse events. The company is partnering with CLIA-certified commercial labs to deliver these important tests into the hands of physicians to meet demand and help patients as quickly as possible

Stephen Diggle MA

Non-Executive Director

Stephen is the founder and Chief Executive Officer of Vulpes Investment Management, and co-founder and former managing partner of Artradis Fund Management, one of the largest hedge fund groups in Asia. Stephen has been involved in equity capital markets for nearly 30 years, leading trading teams across a number of institutions including Salomon Brothers and Lehman Brothers, and has considerable experience investing in and supporting life science businesses through the Vulpes Life Sciences Fund. Stephen holds an MA from the University of Oxford.

Fwiw, just some small top ups

OBD Oxford BioDynamics 20/10/23 24/10/23 3000 OXFD BIOD .34 S Date 24/10/23 £1,038.99

OBD Oxford BioDynamics 20/10/23 24/10/23 3000 OXFD BIOD .34 S Date 24/10/23 £1,038.99

OBD Oxford BioDynamics 20/10/23 24/10/23 3000 OXFD BIOD .34 S Date 24/10/23 £1,038.99

Lol

Even more spooky Tricky, my buying at 34.5 actually moved the market!